Saltar al contenido
Merck

L8668

Levetiracetam

≥98% (HPLC), powder, acetylcholine receptor inhibitor

Sinónimos:

(αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(S)-(2-oxopyrrolidin-1-yl)butyramide

Slide 1 of 1
Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

En este momento no podemos mostrarle ni los precios ni la disponibilidad

Acerca de este artículo

Fórmula empírica (notación de Hill):
C8H14N2O2
Número CAS:
102767-28-2
Peso molecular:
170.21
UNSPSC Code:
12352200
PubChem Substance ID:
329817665
NACRES:
NA.77
MDL number:
MFCD03265610

Documentos clave

Ver Toda la documentación

Saltar a

Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Levetiracetam, ≥98% (HPLC)

SMILES string

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

InChI key

HPHUVLMMVZITSG-LURJTMIESA-N

assay

≥98% (HPLC)

form

powder

color

white

solubility

H2O: >5 mg/mL

originator

UCB Inc.

Quality Level

100

Gene Information

human ... CACNA1B(774), SV2A(9900)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 4

Este artículo
PHR14471359404Y0001253
Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Levetiracetam Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1447

Levetiracetam

Levetiracetam United States Pharmacopeia (USP) Reference Standard

USP

1359404

Levetiracetam

Levetiracetam European Pharmacopoeia (EP) Reference Standard

Y0001253

Levetiracetam

form

powder

form

-

form

-

form

-

assay

≥98% (HPLC)

assay

-

assay

-

assay

-

Quality Level

100

Quality Level

300

Quality Level

-

Quality Level

-

solubility

H2O: >5 mg/mL

solubility

-

solubility

-

solubility

-

color

white

color

-

color

-

color

-

originator

UCB Inc.

originator

-

originator

-

originator

-

Application

Levetiracetam has been used as an anti-epileptic drug to study its effects on glucose-mediated death.[1]

Biochem/physiol Actions

Levetiracetam is a pyrrolidine with antiepileptic activity.
Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Levetiracetam is a member of the pyrrolidone family, which is a second-generation anti-epileptic drug (AED). It acts as a neuroprotective and hyperalgesic drug. Levetiracetam is implicated in cholinergic neurotransmission.[2]

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000482291
0000482290
0000482290
0000482291
0000292970

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Shaikhah Alshuaib et al.
Synapse (New York, N.Y.), 74(8), e22154-e22154 (2020-03-20)
Levetiracetam (LEV) is a widely prescribed antiepileptic drug, but its actions on neuronal function are not fully characterized. Since this drug is believed to enter neurons by binding to a vesicular protein during endocytosis, we used motor axons of the
Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug
Cortes-Altamirano JL, et al.
Neurology India, 64(6), 1266-1266 (2016)
Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation
Wang A, et al.
Cell, 166(6), 1512-1525 (2016)
Hai-Dun Yan et al.
Brain research bulletin, 90, 142-148 (2012-10-31)
Levetiracetam (LEV) is a widely used antiepileptic agent for partial refractory epilepsy in humans. LEV has unique antiepileptic effects in that it does not inhibit electroshock- or pentylenetetrazol-induced convulsion, but does inhibit seizures in kindling animal and spontaneously epileptic rat
Radica M Stepanović-Petrović et al.
Anesthesia and analgesia, 115(6), 1457-1466 (2012-11-13)
We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/anti-edematous effects in the same model of localized inflammation and whether opioidergic
Ver todos los artículos relacionados

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico